Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 735-740

  Kwon, Sanghoon ^a   Kim, Dongbum ^a   Park, Byoung Kwon ^a   Wu, Guang ^a   Park, Min Chul ^a   Ha, Yang Wha ^b   Kwon, Hyung Joo ^a   Lee, Younghee ^b  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

Animal model; CpG; Hepatocellular carcinoma; Liposome; Memory; Peptide vaccine; Prophylaxis; TM4SF5

Indexed keywords

CPG DNA LIPOSOME COMPLEX; PEPTIDE VACCINE; TRANSMEMBRANE 4 SUPERFAMILY MEMBER 5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; IMMUNOLOGICAL MEMORY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CPG ISLANDS; DISEASE MODELS, ANIMAL; EPITOPES; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; KAPLAN-MEIER ESTIMATE; LIPOSOMES; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE;

EID: 84872795127     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2130     Document Type: Article

References (44)

1. Abbas A, Lichtman A and Pillai S (eds): Cellular and Molecular Immunology, 6th edition. Saunders Elsevier, Philadelphia, PA, 2007.
2. Aly HA: Cancer therapy and vaccination. J Immunol Methods 382: 1-23, 2012.
3. Hislop AD, Taylor GS, Sauce D and Rickinson AB: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617, 2007. (Pubitemid 46697918)
4. Finn OJ: Cancer immunology. N Engl J Med 358: 2704-2715, 2008.
5. Schreiber TH, Raez L, Rosenblatt JD and Podack ER: Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin Immunol 22: 105-112, 2010.
6. Bijker MS, Melief CJ, Offringa R and van der Burg SH: Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 6: 591-603, 2007. (Pubitemid 47281301)
7. Bode C, Zhao G, Steinhagen F, Kinjo T and Klinman DM: CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10: 499-511, 2011.
8. Klinman DM, Currie D, Gursel I and Verthelyi D: Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199: 201-216, 2004. (Pubitemid 38736773)
9. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760, 2002. (Pubitemid 34293438)
10. Chu RS, Targoni OS, Krieg AM, Lehmann PV and Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186: 1623-1631, 1997. (Pubitemid 27506276)
11. Carson DA and Raz E: Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. J Exp Med 186: 1621-1622, 1997. (Pubitemid 27506275)
12. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J and Krieg AM: CpG-DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160: 870-876, 1998. (Pubitemid 28049329)
13. Kim D, Rhee J W, Kwon S, Sohn WJ, Lee Y, et al: Immunostimulation and anti-DNA antibody production by backbone modified CpG-DNA. Biochem Biophys Res Commun 379: 362-367, 2009.
14. Lipford GB, Sparwasser T, Zimmermann S, Heeg K and Wagner H: CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 165: 1228-1235, 2000. (Pubitemid 30604548)
15. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, et al: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10: 187-192, 2004. (Pubitemid 38524890)
16. Deng GM, Nilsson IM, Verdrengh M, Collins LV and Tarkowski A: Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 5: 702-705, 1999. (Pubitemid 29289436)
17. Lee KW, Jung J, Lee Y, Kim TY, Choi SY, et al: Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol Immunol 43: 2107-2118, 2006.
18. Henriksen-Lacey M, Korsholm KS Andersen P, Perrie Y and Christensen D: Liposomal vaccine delivery systems. Expert Opin Drug Deliv 8: 505-519, 2011.
19. Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, et al: Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 64: 8754-8760, 2004. (Pubitemid 39552093)
20. Kim D, Kwon S, Rhee J W, Kim KD, Kim YE, et al: Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12: 29, 2011.
21. Kim D, Kwon S, Ahn CS, Lee Y, Choi SY, Park J, Kwon HY and Kwon HJ: Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep 44: 758-763, 2011.
22. Kim D, Kwon HJ and Lee Y: Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep 44: 607-612, 2011.
23. Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, et al: Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest 118: 1354-1366, 2008.
24. Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y and Kwon HJ: Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One 7: e33121, 2012.
25. Yoshiji H, Kuriyama S, Ways DK, Yoshii J and Miyamoto Y: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59: 4413-4418, 1999. (Pubitemid 29418762)
26. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, et al: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7: 1073-1078, 2001. (Pubitemid 32708747)
27. Richard K, Pierce SK and Song W: The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J Immunol 181: 1746-1752, 2008.
28. McHeyzer-Williams LJ and McHeyzer-Williams MG: Antigen-specific memory B cell development. Annu Rev Immunol 23: 487-513, 2005. (Pubitemid 40563178)
29. Hayakawa K, Ishii R, Yamasaki K, Kishimoto T and Hardy RR: Isolation of high-affinity memory B cells: phycoerythrin as a probe for antigen-binding cells. Proc Natl Acad Sci USA 84: 1379-1383, 1987. (Pubitemid 17027357)
30. Ben-Yedidia T and Arnon R: Epitope-based vaccine against influenza. Expert Rev Vaccines 6: 939-948, 2007. (Pubitemid 350260657)
31. Ben-Yedidia T and Arnon R: Design of peptide and polypeptide vaccines. Curr Opin Biotechnol 8: 442-448, 1997. (Pubitemid 27351281)
32. Müller-Pillasch F, Wallrapp C, Lacher U, Friess H, Büchler M, Adler G and Gress TM: Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 208: 25-30, 1998. (Pubitemid 28085272)
33. Lee SA, Ryu HW, Kim YM, Choi S, Lee MJ, et al: Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology 49: 1316-1325, 2009.
34. Lekishvili T, Fromm E, Mujoomdar M and Berditchevski F: The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumor cell motility. J Cell Sci 121: 685-694, 2008. (Pubitemid 351524167)
35. Plotkin SA: Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47: 401-409, 2008.
36. + T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci USA 106: 3877-3882, 2009.
37. Vieira P and Rajewsky K: Persistence of memory B cells in mice deprived of T cell help. Int Immunol 2: 487-494, 1990. (Pubitemid 20218424)
38. Cancro MP: The persistence of memory: a unique niche for IgG memory B cells. Proc Natl Acad Sci USA 107: 12737-12738, 2010.
39. Bernasconi NL, Onai N and Lanzavecchia A: A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504, 2003. (Pubitemid 36857820)
40. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, Cobos E and Kast WM: Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One 5: e10471, 2010.
41. Cerkovnik P, Novakovic BJ, Stegel V and Novakovic S: Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity. BMC Immunol 11: 45, 2010.
42. Chikh G and Schutze-Redelmeier MP: Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 22: 339-353, 2002. (Pubitemid 35222740)
43. + effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine 19: 3608-3614, 2001. (Pubitemid 32522757)
44. Gursel I, Gursel M, Ishii KJ and Klinman DM: Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167: 3324-3328, 2001. (Pubitemid 32852574)